Observational studyFrontiers in endocrinology2026
Association between stress hyperglycemia ratio and acute total occlusion in patients with non-ST-segment elevation myocardial infarction.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute total occlusion (ATO) of the culprit artery identifies a high-risk subgroup of patients with non-ST-segment elevation myocardial infarction (NSTEMI), but its early recognition remains challenging. The stress hyperglycemia ratio (SHR) reflects acute glycemic elevation relative to chronic glycemic status. This study investigated the association between admission SHR and ATO in patients with NSTEMI. Methods: This retrospective, single-center observational cohort study included 827 consecutive patients with NSTEMI who underwent coronary angiography between January 2017 and December 2023. SHR was calculated from fasting plasma glucose and glycated hemoglobin measured at admission. ATO was defined as Thrombolysis in Myocardial Infarction flow grade 0 or 1 in the culprit artery. Receiver operating characteristic analysis was used to assess the discriminatory performance of SHR, and multivariable logistic regression and restricted cubic spline analyses were performed to evaluate its independent and nonlinear associations with ATO. Results: In the overall cohort, SHR showed greater discriminatory performance for ATO (area under the curve, 0.743; 95% confidence interval [CI], 0.708-0.777) than fasting plasma glucose (FPG) (0.706; 95% CI, 0.670-0.742) or glycated hemoglobin (HbA1c) (0.571; 95% CI, 0.531-0.612). The optimal SHR cutoff was 0.903. After multivariable adjustment, SHR >0.903 remained independently associated with higher odds of ATO (adjusted odds ratio, 5.09; 95% CI, 3.66-7.06; P<0.001). Restricted cubic spline analyses further demonstrated significant overall and nonlinear associations between SHR and ATO, which remained robust after covariate adjustment and restriction to the 1st-99th percentile range (all P<0.001). Conclusion: In this retrospective cohort, elevated admission SHR was independently and nonlinearly associated with ATO. Although SHR may complement clinical assessment, further external validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.